Pharmacy benefit managers are the middlemen who decide what your insurance actually pays for a GLP-1 prescription, and this year several states are writing new rules for them. Missouri, New Jersey, and Florida each have bills in motion that touch different parts of that system, from audits to compounding rules to copay assistance. None of these bills has drawn much national attention. But if you fill a GLP-1 prescription in one of these states, the outcome could change what you pay or where you can fill it.
Missouri's SB 984 rewrites the rules PBMs use to audit independent pharmacies, and it caps how often those audits can happen. It also bars contracts that let a PBM charge a patient more at the pharmacy counter than that patient would pay in cash. The bill adds a program aimed at keeping critical access pharmacies open, which matters because those are often the pharmacies serving rural GLP-1 patients. Right now the bill sits on the Senate's informal calendar, waiting for a vote to move it toward the House. If you fill a GLP-1 prescription at an independent pharmacy in Missouri, this bill affects whether that pharmacy stays in business long enough to keep filling it.
New Jersey has two bills moving through its legislature that would tighten what pharmacy boards allow when it comes to compounded GLP-1 preparations. Both bills are classified as restrictive, and they arrive at a moment when the legal status of compounded GLP-1s is already unsettled, since these drugs were recently removed from the FDA's shortage list. That removal changed what pharmacies are allowed to compound in the first place, so New Jersey's bills add a second layer of state-level restriction on top of a federal shift. These bills are moving more slowly than Missouri's, but they are active, and anyone relying on a compounded GLP-1 in New Jersey should keep an eye on them.
Florida's SB 228 would have required insurers and PBMs to count a patient's copay assistance, including manufacturer coupons, toward that patient's actual out-of-pocket maximum. It died in committee in 2024 without reaching a floor vote. That defeat matters beyond Florida, because it showed opponents of copay accumulator bans where and how to stop similar bills before they advance. The idea behind SB 228 has not disappeared, and there is reason to expect it to reappear in Florida's 2026 session. Patients who rely on manufacturer copay assistance for a GLP-1 prescription are the ones this bill was written to protect, and its failure kept that protection out of reach for another cycle.
The same copay accumulator idea that failed in Florida is not confined to Florida. Similar bills are already queued in at least four other states, each proposing to require insurers to count copay assistance toward a patient's deductible or out-of-pocket maximum. That repetition suggests this is less a single-state fight and more a pattern playing out across several legislatures at once. Patients in those states will want to check whether their state is one of the four, since the outcome there will shape whether copay assistance actually lowers what they pay at the pharmacy counter.
Florida also introduced SB 1342, which would have required insurers to give notice before changing a drug's formulary status, and SB 1608, which addressed protections tied to the 340B drug pricing program. Both bills died without ever getting the committee hearing they needed to move forward. Each one addressed a real access problem, from formulary changes that catch patients off guard to pricing protections that hospitals and clinics depend on, but neither made it far enough in the process to reach a vote. Their failure means those specific gaps in Florida's drug pricing rules remain open for now.
If any of these bills is moving in your state, you are not just a bystander in this process. State legislators take calls from constituents, and sponsor names are listed on every bill page for exactly that reason. Committee chairs decide which bills get a hearing and which never move at all, so if you want to see a bill advance, that is who to contact. Watching bill numbers is useful, but reaching out is what actually changes whether these votes happen.
Key details
Missouri's SB 984 caps PBM audits and bars overcharging patients at independent…
New Jersey has two bills that would limit compounded GLP-1 preparations through pharmacy…
Florida's SB 228, a copay accumulator ban, died in 2024 but may return in 2026.
Similar copay accumulator bans are already queued in at least four other states.
Florida's SB 1342 and SB 1608, on formulary transparency and 340B, both died without a…